Elanco Animal Health Inc·4

Feb 24, 4:44 PM ET

Simmons Jeffrey N 4

Research Summary

AI-generated summary

Updated

Elanco (ELAN) CEO Jeffrey N. Simmons Receives Deferred Stock Award

What Happened

  • Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc., was granted 110.858 deferred stock units on Feb 20, 2026. The units are reported at $24.98 per share, for a reported aggregate value of $2,769. This was an award (derivative security), not an open-market purchase.

Key Details

  • Transaction type/code: Award of deferred stock units (Form 4 code "A", derivative).
  • Date and price: 2026-02-20 at $24.98 per unit; total reported value $2,769.
  • Shares owned after transaction: Not specified in the supplied filing details.
  • Settlement/vesting note: Each deferred stock unit represents the right to one share or the cash equivalent (Footnote F1). Units settle in cash or shares following termination of employment or during a specified future year per the Executive Deferral and Stock Match Plan (Footnote F2).
  • Filing timeliness: Form 4 was filed on 2026-02-24, within the standard 2-business-day reporting window for insiders.

Context

  • This was a compensation award (deferred stock units), which typically reflects executive pay and vesting/deferral choices rather than an immediate market buy or sell decision. Deferred units convert to cash or shares later, so they do not represent immediate open-market ownership or a liquidity event.